To investigate myeloid cell heterogeneity and infiltrate, we obtained patient-matched PBMCs, NAT, and ccRCC and stained for myeloid markers to analyze by flow cytometry (Fig. 1A–1B; supplemental Table S1, supplemental Fig. S1). The gene discussed is BRD2; the disease is nonpapillary renal cell carcinoma.